Could vitamin B3 save sight in rare optic nerve disease?
NCT ID NCT06007391
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether high-dose nicotinamide (vitamin B3) is safe and can help people with dominant optic atrophy, a rare genetic disease that slowly damages the optic nerve and causes vision loss. Researchers will give 25 adults 3 grams of nicotinamide daily and monitor for side effects and changes in eye function. There is currently no approved treatment for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nicotinamide (vitamin B3)
- What this could lead to
- If it works, this could point toward a simple vitamin supplement to slow vision loss in dominant optic atrophy and similar nerve diseases.
- What could go wrong
- This is a small pilot study with only 25 people, so results may not apply widely. The dose is high and could cause side effects, and the benefit is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOMINANT OPTIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Angers University Hospital
Angers, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.